Septerna, Inc. Common Stock SEPN

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

• GlobeNewswire Inc. 10 sept

  Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Septerna, Inc. announced the grant of 275,000 non-qualified stock options to Dr. Rajiv Patni, the company's newly appointed Chief Medical Officer. The options have an exercise price of $37.37 per share, a ten-year term, and vest over four years with 25% vesting after one year and the remainder vesting monthly over 36 months.

  

• GlobeNewswire Inc. 1 sept

  Septerna to Participate in Upcoming Investor Conferences

  Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company focused on GPCR drug discovery, announced participation in two investor conferences in September 2026. The company also appointed industry veteran Rajiv Patni, M.D., as Chief Medical Officer. Septerna is advancing its Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist, with SAD/MAD data expected in Q1 2027.

  

• GlobeNewswire Inc. 25 ago

  Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

  Septerna, Inc. announced the appointment of Dr. Rajiv Patni as Chief Medical Officer. Dr. Patni brings over 25 years of biopharmaceutical experience and has contributed to 10 regulatory approvals across multiple companies. He joins from Judo Bio where he served as CEO and will lead Septerna's clinical development efforts for its GPCR-targeted drug pipeline.

  

• The Motley Fool 5 jul

  Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

  Septerna's Chief People Officer Samira Shaikhly sold 11,798 shares worth approximately $355,000 on May 26, 2026, reducing her direct holdings by 93.7%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in October 2025, indicating a non-discretionary transaction designed to avoid insider trading accusations. Despite the large insider sale, the company reported positive clinical trial progress and maintains strong cash reserves of $522.1 million, sufficient to fund operations into 2029.

  

• The Motley Fool 29 jun

  Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

  Septerna SVP Daniel D. Long exercised and sold 15,000 shares for ~$533,000 on June 22, 2026, reducing his direct holdings by 13.46%. The analyst suggests this appears to be routine income supplementation rather than a loss of confidence, as Long retains 96,412 shares and 36,000 unexercised options. Septerna, a clinical-stage biotech developing GPCR-targeted therapies, has shown positive phase 1 results for SEP-631 and maintains partnerships with Novo Nordisk.